Completed NCT00392743
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Barcelona Schizophrenia Other Over 18 Years
Countries Spain
Sponsor GlaxoSmithKline
Condition Schizophrenia Withdrawn NCT02418702
This summary needs review. Please check the official study record and contact the research team for details.
In San Diego Depression Drug i A study involving a medication or substance. From 18 Years to 65 Years
Countries United States
Sponsor United States Naval Medical Center, San Diego
Condition Depression Completed NCT04463108
This study is completed in Italy. It focuses on depression.
Multiple locations, including Brescia Depression, Suicidality Other From 18 Years to 74 Years
Countries Italy
Sponsor Janssen-Cilag S.p.A.
Condition Depression, Suicidality Completed NCT00518232
This study is completed. It focuses on ADHD.
Location not clearly listed ADHD Drug From 6 Years to 19 Years
Countries
Sponsor Johnson & Johnson Taiwan Ltd
Condition ADHD Completed NCT03751488
This study is completed in the United States. It is testing Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® for schizophrenia.
Multiple locations, including Garden Grove Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor Luye Pharma Group Ltd.
Condition Schizophrenia Completed NCT00212797
This study is completed. It is testing 2 Doses of Org 34517 for depression.
Location not clearly listed Depression, Schizophrenia Drug From 18 Years to 70 Years
Countries
Sponsor Merck Sharp & Dohme LLC
Condition Depression, Schizophrenia Completed NCT03627195
This study is completed in the United States. It focuses on schizophrenia.
In Long Beach Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor Sumitomo Pharma America, Inc.
Condition Schizophrenia Completed NCT02624167
This study is completed in the United States and in India. It focuses on schizophrenia.
Multiple locations, including Garden Grove Schizophrenia Drug From 18 Years to 65 Years
Countries United States, India
Sponsor Newron Pharmaceuticals SPA
Condition Schizophrenia Completed NCT00880217
This study is completed in the United States. It is testing 3 Different Doses of JNJ-31001074 for ADHD.
Multiple locations, including Little Rock ADHD Drug From 18 Years to 55 Years
Countries United States
Sponsor Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Condition ADHD Completed NCT03382639
This study is completed in the United States, in Bulgaria, in Czechia, .... It focuses on schizophrenia.
Multiple locations, including Garden Grove Schizophrenia Drug From 18 Years to 60 Years
Countries United States, Bulgaria, Czechia, ...
Sponsor Neurocrine Biosciences
Condition Schizophrenia Completed NCT03107026
This study is completed in the United States. It is testing drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, for Eating disorders.
Multiple locations, including Phoenix Eating disorders Drug From 18 Years to 55 Years
Countries United States
Sponsor Sumitomo Pharma America, Inc.
Condition Eating disorders Completed NCT01655680
This study is completed in the United States, in the United Kingdom, and in Russia. It is testing ABT-126 for schizophrenia.
Multiple locations, including Anaheim Schizophrenia Drug From 20 Years to 65 Years
Countries United States, United Kingdom, Russia
Sponsor AbbVie (prior sponsor, Abbott)
Condition Schizophrenia